The reduction in plaque volume during stent implantation is associated with the release of particulate debris and plaque-derived soluble substances. We studied the potential release of the pro-inflammatory cytokine tumor necrosis factor alpha (TNF ) into the coronary circulation and whether such release is related to the reduction in plaque volume and possibly a predictor for restenosis.
Introduction
The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF ) has been localized in human atheromatous plaques (1, 24, 28) and it contributes to plaque progression, destabilization and rupture (25, 27) , as well as to the progression of restenosis (11, 13, 15) .
The reduction in plaque volume during coronary stent implantation involves plaque compression, axial redistribution and/or disruption (19, 26) . The reduction in plaque volume is also associated with the release of particulate debris as well as of soluble vasomotor and thrombogenic substances into the coronary circulation (7, 10) . Recently, using a distal balloon protection device, which traps and aspirates particulate debris as well as soluble substances during stent implantation, we identified serotonin and thromboxane A2 as potent vasoconstrictors in the aspirate from atherosclerotic saphenous vein aortocoronary bypass grafts (SVG). Both substances were released in relation to the angiographic severity of the stenosis and to plaque volume as determined by intravascular ultrasound (10).
In the present study we used the same approach to investigate whether TNF is also released into the coronary circulation and whether such release is related to the reduction in plaque volume and possibly a predictor for restenosis.
In situ, veins do not have an external elastic membrane. However, arterialized SVG undergo morphologic changes (intimal fibrous thickening, medial hypertrophy, lipid deposition) so that a echo lucent zone, which has been reported to represent the media, can be identified by IVUS. Therefore, the external elastic membrane (EEM) area was measured by tracing the outer border of this echo lucent zone (5, 29). Plaque area (-volume) was calculated as EEM minus lumen area (-volume) . Patients´ individual N plaque volume was calculated as plaque volume before the intervention minus plaque volume after the intervention.
Interventional procedure
Implantation of balloon-expandable stents (eleven bare metal stents, eleven paclitaxel-eluting using maximum balloon pressures of T14 atm and a balloon to vessel ratio of 1.1. To prevent microembolization, a distal balloon occlusion device (TriAktiv®, Kensey Nash, Exton, PA, USA) was mounted on a guide wire and inflated at 2 atm with CO 2 during stent implantation.
Aspiration of plaque debris was performed via the guiding catheter after a special flushing catheter was advanced proximal to the inflated wire balloon. During slow withdrawal of the flushing catheter the stented area was washed with saline. After the extraction process the balloon was deflated and a post-interventional angiography was performed.
Blood samples and determination of plasma TNF -levels
Prior to intervention, arterial blood was taken distal to the stented lesion via the flushing catheter (20 ml; into potassium-EDTA S-Monovette) and compared to the aspirate which was flushed out after stent implantation, resulting in approximately two-fold dilution with saline, and filtered through a 40 Vm mesh filter. In each instance, visible particulate debris was retained on the filter. Arterial blood and filtered aspirate were immediately centrifuged (600 g 7 for 10 min at 4°C), the plasma was removed, quickly frozen in liquid nitrogen and stored at -20°C until further use. Plasma TNF -levels were determined using a solid-phase, chemiluminescent immunometric assay (IMMULITE /IMMULITE 1000 TNF ; DPC, Gwynedd, UK). The individual increase in the plasma TNF -level (= TNF -levels in pg/ml) was calculated for each patient.
Statistics
Data are mean values±SE. Statistical differences were assessed with paired (angiographic, IVUS-and TNF -levels before vs. after stenting) or unpaired (comparison of BMS vs. DES and restenosis <50% vs. >50%) two-sided Students´ t-tests. Linear correlations were calculated, and all statistics were done with the Prism program (Graph-Pad Software, San Diego, CA, USA). A p-value<0.05 was considered significant.
Results

Baseline and post-interventional angiographic and IVUS data
Before stent implantation, the percent diameter stenosis of the SVG was 63±1 % and the plaque volume was 223±27 mm 3 (n=24 stents). Immediately after stent implantation, the diameter stenosis was reduced to 4±1 % and the plaque volume to 183±24 mm 3 (n=24 stents), each p<0.0001 vs. before stenting. The reduction in diameter stenosis was related to baseline diameter stenosis (r=0.76, p<0.0001; n=24 stents), and the reduction in plaque volume was related to baseline plaque volume (r=0.56, p=0.0041; n=24 stents).
Aspirate TNF -levels before and after stent implantation and relation to plaque extrusion
In each patient, the aspirate TNF -level increased after stent implantation. Before stenting the mean TNF -level was 9±1 pg/ml and increased after stent implantation to 28±3 pg/ml (n=24 stents, p<0.0001; see Figure 1A ). The increase in TNF ( TNF ) correlated with baseline plaque volume (r=0.44, p=0.0319; n=24 stents) and with the reduction in plaque volume (see Figure 1B) .
We found no relationships between TNF and the reduction in diameter stenosis, stent length, mechanical deformation (measured as increase in vessel cross sectional area after stent implantation), or graft age.
Periprocedural increase in aspirate TNF -levels in relation to restenosis
Five months after stent implantation the mean lumen diameter was reduced to 2.28±0.34 mm (p<0.0001 vs. immediately after stenting with 3.58±0.14 mm; n=18 stents), i.e. restenosis averaged 38±9 % (n=18 stents). The patients´ individual restenosis correlated significantly with the periprocedural increase in TNF -level (n=18 stents, see Figure 1C ).
immediately after stenting ( TNF 33±8 pg/ml, n=6 stents) than patients with restenosis <50% ( TNF 17±3 pg/ml, n=12 stents, with p=0.0355), while they did not differ in their baseline TNF -levels (>50%: 10±2 pg/ml (n=6 stents) vs. <50%: 9±2 pg/ml (n=12 stents)).
The degree of restenosis was independent from the implantation of a DES (36±14 % with a TNF level of 19±4 pg/ml, n=8 stents) or a BMS (39±12 % with a TNF level of 24±5 pg/ml, n=10 stents).
Discussion
In native coronary vessels, TNF contributes to the progression from stable to unstable plaques by augmenting the local inflammatory response via multiple effects (11, 19, 25, 27) .
TNF -induced effects include the release of cell surface adhesion molecules (13), the increase in thrombotic activity (21) and the induction of endothelial and smooth muscle cell apoptosis by increased formation of reactive oxygen species within the plaque (3). TNF also causes plaque instability by increasing the level of matrix degrading enzymes, such as matrix metalloproteinases (4). Increased levels of TNF with plaque progression are seen predominantly in the cytoplasm and attached to the plasma membrane of macrophages, endothelial and smooth muscle cells (1, 17). Of note, TNF also contributes to coronary endothelial dysfunction in ischemia/reperfusion (30) and is also the mediator of contractile dysfunction after embolization of plaque debris into the coronary microcirculation (23).
In contrast to native coronary artery lesions, SVG plaques contain more foam and inflammatory cells, and a poorly developed or absent fibrous cap with relatively low calcium content. Therefore, SVG plaques are per se more fragile and prone to rupture (16, 18) , but the relation of plaque vulnerability to TNF is not clear. In the present study, we now demonstrate that TNF is indeed released into the aspirate of stented SVG and that this release is related to the reduction in plaque volume and to restenosis.
The correlation of periprocedural TNF release to the reduction in plaque volume suggests, that TNF simply reflects the amount of atherosclerosis. On the other hand, the relation of periprocedural TNF release to restenosis suggests, that TNF also reflects the activity of the atherosclerotic process. In this respect, the released TNF may be a mirror of the TNF retained in the vascular wall. Since we found no relation of periprocedural TNF release to stent length or increase in vessel cross sectional area after stent implantation, mechanical injury per se is probably not responsible for TNF release (8) and restenosis (20).
These findings confirm and extend the observation that restenosis is not a random event, but affects selectively a subset of patients, possibly those with high intra-plaque TNF -levels prior to stenting. TNF has been suggested as a predictor for restenosis before (9). However, in this prior study the preprocedural peripheral blood levels of TNF , reflecting systemic inflammation, in patients with stable angina and a small group of patients with unstable angina predicted the rate of restenosis of native coronary artery lesions. In contrast, in our present study, the periprocedural increase in TNF at the site of the stented SVG lesion predicted the degree of that individual stenosis 5 months later, thus establishing an even firmer cause-effect relationship. In those patients, the neutralization of TNF with locally applied TNF -antibodies or the use of TNF -antibody-eluting stents could be promising (8, 22) .
Our data are limited to a small number of patients. Future studies in a larger cohort of patients will have to confirm the potential prognostic value of periprocedural TNF -release for restenosis, and threshold values will need to be determined by receiver-operator characteristics and then analyzed as predictors in a multivariate approach.
Also, SVG plaques are particularly vulnerable to rupture and therefore our findings must be extrapolated to native coronary plaques and their possibly subclinical rupture in daily life with care. Nevertheless, aspiration of plaque material and soluble factors during stenting of SVG is an ethical approach to study pathogenic factors under controlled conditions. 
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